GO 6976

The Uses of GO 6976

Go 6976 is a potent FLT3 inihibtor which is been shown to initiate cytotoxicity involving acute leukemia. Also known as a PKC inhibitor, which results into apoptosis and tumor destruction. Cancer therapeutic agent.

What are the applications of Application

G? 6976 is an inhibitor of certain forms of PKC, Trks, and JAKs

Definition

ChEBI: Goe 6976 is an organic heterohexacyclic compound and an indolocarbazole. It has a role as an EC 2.7.11.13 (protein kinase C) inhibitor.

Biological Activity

Potent protein kinase C (PKC) inhibitor (IC 50 = 7.9 nM). In vitro, discriminates between Ca 2+ -dependent and -independent isoforms of PKC; selectively inhibits PKC α and PKC β 1 (IC 50 values are 2.3 and 6.2 nM respectively) but does not inhibit the activity of PKC δ , - ε , or - ζ (IC 50 > 3 μ M). Also inhibits TrkA, TrkB, JAK2 and JAK3 tyrosine kinases (IC 50 values are 5, 30, 130 and 370 nM respectively).

storage

-20°C (desiccate)

References

[1]. gschwendt, m., et al., inhibition of protein kinase c mu by various inhibitors. differentiation from protein kinase c isoenzymes. febs lett, 1996. 392(2): p. 77-80.
[2]. qatsha, k.a., et al., go 6976, a selective inhibitor of protein kinase c, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. proc natl acad sci u s a, 1993. 90(10): p. 4674-8.
[3]. joksovic, p.m., et al., mechanisms of inhibition of t-type calcium current in the reticular thalamic neurons by 1-octanol: implication of the protein kinase c pathway. mol pharmacol, 2010. 77(1): p. 87-94.
[4]. taube, e., et al., a novel treatment strategy for egfr mutant nsclc with t790m-mediated acquired resistance. int j cancer, 2012. 131(4): p. 970-9.
[5]. yoshida, a., et al., go6976, a flt3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and mcl-1. biochem pharmacol, 2014. 90(1): p. 16-24.